Thus, orally-administered small molecule NHE3 inhibitors, such as AVE0657 [113] and AZD1722 (Tenapanor), have shown potent effects on the blockage of either renal or intestinal afferent Na+ absorption and control of hypertension [115]. The gene discussed is SLC9A3; the disease is hypertensive disorder.